Sector News

Integra LifeSciences Completes Acquisition of TEI Biosciences and TEI Medical

July 20, 2015
Life sciences
(GLOBE NEWSWIRE) – Integra LifeSciences Holdings Corporation (NASDAQ:IART), today announced that it has completed the acquisition of all of the outstanding shares of TEI Biosciences Inc. and TEI Medical Inc. (“TEI”). 
 
“We are enthusiastic about the strategic fit of these two organizations, and the positive impact TEI has on both top and bottom-line metrics,” stated Peter Arduini, Integra’s President and Chief Executive Officer.  “With this acquisition, we have a significant opportunity to build our platform and fuel a robust pipeline of regenerative products to accelerate Integra’s overall growth.”
 
“The combined organization will offer surgeons a leading regenerative technology platform for indications in soft tissue reconstruction and wound repair,” said Mark Augusti, Integra’s CVP and President, Orthopedics and Tissue Technologies. “In addition to TEI’s complementary call points in the wound care clinic and operating room, TEI’s products provide surgeons with different strength and handling characteristics.”
 
Glenn Coleman, Integra’s CVP and Chief Financial Officer added, “Strategically, the acquisition of TEI advances our plans to be a leader in regenerative technology, accelerates our entry into the diabetic foot ulcer market, expands our call point in wound care and tissue repair, and is accretive to our financial objectives.” 
 
Integra announced this acquisition on June 28, 2015. Integra will provide further details regarding the financial impact of this acquisition on its second quarter 2015 financial results conference call, scheduled for July 30, 2015.
 
Source: Integra
 

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend